neoplasm
• 84% of early generation mutants succumb to tumors with a median tumor-free latency of 71.6 weeks
• late generation mutants show a decrease in percent tumor death and an increase in tumor-free latency, from 84% to 20% and 71.6-104.9 weeks
|
• 19% and 23% of early generation and late generation mutants, respectively, develop lymphomas
|
• 35% and 39% of early generation and late generation mutants, respectively, develop histocytic sarcomas
• 20% and 23% of early generation and late generation mutants, respectively, develop soft tissue sarcomas
|